COVID-19 – Pipeline Analysis 2020 for Global Market

COVID-19 – Pipeline Analysis 2020 for Global Market

Emphasis on Products covered by Phase (Phase III, Phase II, Phase I, Investigational New Drug, Pre-clinical, Discovery); Therapeutic Assessment by Stages (Product Type, Route of Administration, Molecule Type) and Company

$ 2000
$2800
$3920

Published: Apr-2020

Pages:164

Table:69

Figure: 26

Report ID:UMHE20178

COVID-19 (also known as Anderson COVID-19) is a viral disease caused by RNA virus, SARS-CoV-2 or commonly known as corona virus. These viruses can cause respiratory, enteric, hepatic, and neurologic diseases. At the end of 2019, a new coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, China. It rapidly spread, resulting in an epidemic throughout China, followed by an increasing number of cases in other countries throughout the world. On March 11, 2020 World Health Organization (WHO) declared it a pandemic.

COVID-19 is mainly transmitted through contact with respiratory droplets rather than through the air and spreads primarily through contact with an infected person when they cough or sneeze. It also spreads when a person touches a surface or object that has the virus on it, then touches their eyes, nose, or mouth. A patient might take 1 to 14 days before developing symptoms as corona virus has an incubation period of 14 days. The most common symptoms of COVID-19 include dry cough, tiredness, fever and difficulty breathing (severe cases). Some patients may also suffer from aches and pains, runny nose, nasal congestion, sore throat or diarrhoea.

Split of Therapeutic Products

The diagnosis of the disease can be done by several methods such as nucleic acid test, serologic diagnosis and imaging technology. Chest radiograph or CT is an important tool for COVID-19 diagnosis in clinical practice. The majority of Covide-19 cases have similar features on CT images. Currently no antiviral treatment available for SARS-CoV-2 however, companies and research institutes are working towards it. Therapeutic agents targeting nucleosides, nucleotides, viral nucleic acids and enzymes/proteins involved in the replication and transcription of coronaviruses can be promising strategies to treat coronavirus diseases.

The pipeline of COVID-19 consists of approximately 85+ products in different stages of development. It includes therapeutic drugs and vaccines. Currently, 8+ drugs are in Phase III development and major drugs are in pre-clinical stage. Moreover, 42 vaccines are under development by various companies, and 2+ vaccines are in Phase I trial.

Top Company Analysed

Some of the key players include in the analysis includes Ascletis Pharma Inc., OncoImmune, FUJIFILM Toyama Chemical Co., Ltd.; Sanofi, Gilead Sciences, Incyte Corporation, Hoffmann La Roche, Vanda Pharmaceuticals, Apeiron Biologics and Relief Therapeutics Holdings among others.

Scope of the COVID-19 - Pipeline Analysis 2020:

  • The report provides an overview of therapeutic pipeline activity for COVID-19 across the complete product development cycle including all clinical and non-clinical stages
  • The report comprises of detailed profiles of COVID-19 therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Detailed profiles of the clinical vaccines and listing of the non-clinical vaccines under development by companies
  • Listing of the vaccines under development by universities

Reasons to buy:

  • The COVID-19 pipeline report presents the detailed profile of drugs. The analysis offered in the report is a combination of deep dive secondary research and input from Key Opinion Leader of the industry
  • The report presents a quick review of the current scenario regarding the drug development of the indication at one glance
  • The report covers in-depth analysis of prominent industry peers with a primary focus on company consolidation, technology, agreements and patents regarding the therapy
  • Detailed examination on diagnosis and treatment prevailing in the industry
  • The study comprehensively covers the market across drugs in different phases of development

Customization Options:

The COVID-19 Pipeline analysis report can be customized to the country level or any other competitive segment. Besides this, UMI understands that you may have your own business need, hence we also provide fully customized solutions to clients.

    1.1 Objective of the Study
    1.2 Limitation    
    1.3 Stakeholders    
    1.4 Currency used in the Report
    1.5 Secondary Research  
    1.6 Scope of the COVID-19 – Pipeline Analysis Study
  2 RESEARCH METHODOLOGY OR ASSUMPTION
    2.1 Research Methodology for the COVID-19 – Pipeline Analysis 2020
      2.1.1 Main objective of the COVID-19 – Pipeline Analysis 2020
  3 EXECUTIVE SUMMARY  
  4 DISEASE OVERVIEW    
    4.1 Introduction    
    4.2 Etiology    
    4.3 Virology    
      4.3.1 Physicochemical Properties
      4.3.2 Receptor Interactions and Cell Entry
    4.4 Diversity of Coronaviruses
    4.5 Epidemiology and clinical features of human coronaviruses
      4.5.1 Source of Infection
      4.5.2 Spectrum of Infection
      4.5.3 Clinical Features
      4.5.4 Epidemiological Characteristics in Mainland China and other countries
      4.5.5 Herd Susceptibility
    4.6 Pathogenesis    
      4.6.1 Virus Entry and Spread
      4.6.2 Pathological Findings
      4.6.3 Acute Respiratory Distress Syndrome (ARDS)
      4.6.4 Cytokine Storm
      4.6.5 Immune Dysfunction
    4.7 Signs and Symptoms  
    4.8 Diagnostic testing  
      4.8.1 Nucleic Acid Test
      4.8.2 Serologic Diagnosis
      4.8.3 CRISPR/Cas13 System
      4.8.4 Imaging Technology
    4.9 Treatment    
      4.9.1 Type I IFNs  
      4.9.2 Convalescent Plasma
      4.9.3 Protective Monoclonal Antibody
      4.9.4 Protease  
      4.9.5 Others  
      4.9.6 Vaccines  
      4.9.7 Proposed COVID-19 Triage Algorithm for Low-income Settings Without Established Local Transmission
  5 PIPELINE THERAPEUTICS AT A GLANCE
    5.1 General Overview (Clinical Stage Products)
    5.2 General Overview (Non-Clinical Stage Products
  6 CLINICAL PRODUCTS UNDER DEVELOPMENT BY TARGET
  7 COMPARATIVE ANALYSIS  
    7.1 General Overview  
  8 LATE PHASE PRODUCTS (PHASE III)
    8.1 Comparative Analysis
    8.2 ASC09+Ritonavir: Ascletis Pharmaceuticals Co., Ltd.
      8.2.1 Product Description
      8.2.2 Research and Development
        8.2.2.1 Clinical Studies
          8.2.2.1.1 Phase III
      8.2.3 Product Development Activities
        8.2.3.1 Collaboration
    8.3 CD24Fc: OncoImmune
      8.3.1 Product Description
      8.3.2 Research and Development
        8.3.2.1 Clinical Studies
          8.3.2.1.1 Phase III
    8.4 Favipiravir: FUJIFILM Toyama Chemical Co., Ltd.
      8.4.1 Product Description
      8.4.2 Research and Development
        8.4.2.1 Clinical Studies
          8.4.2.1.1 Phase III
    8.5 Hydroxychloroquine: Sanofi-Aventis
      8.5.1 Product Description
      8.5.2 Research and Development
        8.5.2.1 Clinical Studies
          8.5.2.1.1 Phase III
    8.6 Remdesivir: Gilead Sciences
      8.6.1 Product Description
      8.6.2 Research and Development
        8.6.2.1 Pre-clinical Studies
        8.6.2.2 Clinical Studies
          8.6.2.2.1 Phase III
    8.7 Ruxolitinib: Incyte Corporation
      8.7.1 Product Description
      8.7.2 Research and Development
        8.7.2.1 Clinical Studies
          8.7.2.1.1 Phase III
      8.7.3 Product Development Activities
        8.7.3.1 Collaboration Agreement
    8.8 Tocilizumab: Hoffmann-La Roche
      8.8.1 Product Description
      8.8.2 Research and Development
        8.8.2.1 Clinical Studies
          8.8.2.1.1 Phase III
    8.9 Tradipitant: Vanda Pharmaceuticals
      8.9.1 Product Description
      8.9.2 Research and Development
        8.9.2.1 Clinical Studies
          8.9.2.1.1 Phase III
      8.9.3 Product Development Activities
        8.9.3.1 Licensing Agreement
        8.9.3.2 Patent
  9 MID PHASE PRODUCTS (PHASE II)
    9.1 Comparative Analysis
    9.2 APN-01: Apeiron Biologics
      9.2.1 Product Description
      9.2.2 Research and Development
        9.2.2.1 Clinical Studies
          9.2.2.1.1 Phase II
      9.2.3 Product Development Activities
        9.2.3.1 Acquisition Agreement
    9.3 Aviptadil: Relief Therapeutics
      9.3.1 Product Description
      9.3.2 Research and Development
        9.3.2.1 Clinical Studies
          9.3.2.1.1 Phase II
      9.3.3 Product Development Activities
        9.3.3.1 Divestment Agreement
        9.3.3.2 IND Application
        9.3.3.3 Acquisition Agreement
    9.4 BXT-10: Bioxytran  
      9.4.1 Product Description
      9.4.2 Research and Development
        9.4.2.1 Pre-clinical Studies
        9.4.2.2 Clinical Studies
          9.4.2.2.1 Phase II
      9.4.3 Product Development Activities
        9.4.3.1 Licensing
    9.5 Leronlimab: CytoDyn
      9.5.1 Product Description
      9.5.2 Research and Development
        9.5.2.1 Clinical Studies
          9.5.2.1.1 Phase II
      9.5.3 Product Development Activities
        9.5.3.1 Acquisition Agreement
    9.6 Lopinavir+Ritonavir: AbbVie
      9.6.1 Product Description
      9.6.2 Research and Development
        9.6.2.1 Clinical Studies
          9.6.2.1.1 Phase II
      9.6.3 Product Development Activities
        9.6.3.1 Collaboration
    9.7 Plitidepsin: PharmaMar
      9.7.1 Product Description
      9.7.2 Research and Development
        9.7.2.1 Preclinical Studies
        9.7.2.2 Clinical Studies
          9.7.2.2.1 Phase II
    9.8 Sarilumab: Sanofi-Aventis
      9.8.1 Product Description
      9.8.2 Research and Development
        9.8.2.1 Clinical Studies
          9.8.2.1.1 Phase II/III
      9.8.3 Product Development Activities
        9.8.3.1 Collaboration Agreement
        9.8.3.2 Technology
    9.9 SNG001: Synairgen Research
      9.9.1 Product Description
      9.9.2 Research and Development
        9.9.2.1 Clinical Studies
          9.9.2.1.1 Phase II
      9.9.3 Product Development Activities
        9.9.3.1 Technology
  10 EARLY STAGE PRODUCTS (PHASE I and IND)
    10.1 Comparative Analysis
    10.2 AmnioBoost: Lattice Biologics
      10.2.1 Product Description
      10.2.2 Research and Development
        10.2.2.1 Clinical Studies
          10.2.2.1.1 Phase I
    10.3 Baloxavir marboxil/Favipiravir and Lopinavir/Ritonavir: Shionogi & Co., Ltd.
      10.3.1 Product Description
      10.3.2 Research and Development
        10.3.2.1 Clinical Studies
          10.3.2.1.1 Phase 0
    10.4 Gimsilumab: Roivant Sciences
      10.4.1 Product Description
      10.4.2 Research and Development
        10.4.2.1 Clinical Studies
          10.4.2.1.1 Phase I
    10.5 REGN3048+REGN3051: Regeneron Pharmaceuticals
      10.5.1 Product Description
      10.5.2 Research and Development
        10.5.2.1 Pre-clinical Studies
        10.5.2.2 Clinical Studies
          10.5.2.2.1 Phase I
      10.5.3 Product Development Activities
        10.5.3.1 Collaboration Agreement
        10.5.3.2 Technology
    10.6 Ifenprodil: Algernon Pharmaceuticals
      10.6.1 Product Description
      10.6.2 Research and Development
        10.6.2.1 Pre-clinical Studies
        10.6.2.2 Clinical Studies
          10.6.2.2.1 Planned Phase II
      10.6.3 Product Development Activities
        10.6.3.1 Recent Initiatives towards COVID-19 Pandemic
        10.6.3.2 Manufacturing Agreement
        10.6.3.3 IND Application
        10.6.3.4 Contract Agreement
    10.7 Remestemcel-L: Mesoblast
      10.7.1 Product Description
      10.7.2 Research and Development
        10.7.2.1 Clinical Studies
          10.7.2.1.1 Phase II/III
      10.7.3 Product Development Activities
        10.7.3.1 IND Application
        10.7.3.2 Partnership
        10.7.3.3 Licensing Agreement
    10.8 TJM2: I-Mab Biopharma
      10.8.1 Product Description
      10.8.2 Research and Development
        10.8.2.1 Clinical Studies
          10.8.2.1.1 Phase I
      10.8.3 Product Development Activities
        10.8.3.1 IND Application
  11 PRE-CLINICAL AND DISCOVERY STAGE PRODUCTS
    11.1 Comparative Analysis
  12 THERAPEUTIC ASSESSMENT (CLINICAL PRODUCTS)
    12.1 Assessment by Stage and Product Type
    12.2 Assessment by Stage and Product Type
    12.3 Assessment by Route of Administration
    12.4 Assessment by Stage and Route of Administration
    12.5 Assessment by Molecule Type
    12.6 Assessment by Stage and Molecule Type
  13 EXECUTIVE SUMMARY  
  14 VACCINES UNDER DEVELOPMENT BY COMPANIES
    14.1 Clinical Stage Vaccines
      14.2 Ad5-nCoV: CanSino Biologics Inc.
      14.2.1 Product Description
      14.2.2 Research and Development
        14.2.2.1 Pre-clinical Studies
        14.2.2.2 Clinical Studies
          14.2.2.2.1 Phase I
      14.2.3 Product Development Activities
        14.2.3.1 Technology
    14.3 mRNA-1273: Moderna Inc.
      14.3.1 Product Description
      14.3.2 Research and Development
        14.3.2.1 Clinical Studies
          14.3.2.1.1 Phase I
      14.3.3 Product Development Activities
        14.3.3.1 Funding
    14.4 INO-4800: Inovio Pharmaceuticals
      14.4.1 Product Description
      14.4.2 Research and Development
        14.4.2.1 Pre-clinical Studies
        14.4.2.2 Clinical Studies
          14.4.2.2.1 Phase I
      14.4.3 Product Development Activities
        14.4.3.1 Collaboration
        14.4.3.2 Funding
    14.5 Non-Clinical Stage Vaccines
  15 VACCINES UNDER DEVELOPMENT BY UNIVERSITIES

Research Methodology for COVID-19 - Pipeline Analysis 2020

Overview of pipeline development activities for COVID-19 is not limited to drug description and development activities but also focuses on clinical and pre-clinical results. It also includes company collaboration, licensing deals, funds, and technology and patent details. Therapeutic segmentation of products for COVID-19 is done based on different stage of development. The report comprises of comparative pipeline therapeutics assessment along with detailed drug and vaccine profile of pipeline products by development stage, therapy type, molecule type, and administration route across this indication. Additionally, Executive summary have also been focused upon to give a summary regarding the current market scenario. The detailed profiles of the clinical vaccines products have been elucidated in the complete report and the non-clinical vaccines under development by companies and universities have also been listed.

Secondary Research

Detail secondary study was conducted to obtain the COVID-19 Pipeline Analysis through company internal sources such as quarterly reports, performance presentations, press releases, etc., and external sources including trade journals, news & articles, government publications, competitor publications, sector reports, regulatory body’s publications, safety standard organizations, third-party database and other creditable publications.

The secondary research on internal and external sources is being carried out to source qualitative and quantitative information relating to each market.

  • Company websites, quarterly reports, financial reports, broker reports, investor presentations and SEC filings
  • Industry trade journals and other literature
  • National government documents, statistical databases and market reports
  • News articles, press releases and web-casts specific to the companies operating in the market
  • Several databases for patents and clinical trials

Main objective of the COVID-19 - Pipeline Analysis 2020

The current pipeline trends of the COVID-19 are pinpointed in the study. Investors can gain strategic insights to base their discretion for investments from the qualitative and quantitative analysis performed in the study. Current and future pipeline trends would determine the overall attractiveness of the market, providing a platform for the industrial participant to exploit the untapped market to benefit as first mover advantage. The quantitative objectives for the report include:

  • Detailed overview of the indication including etiology, virology, diversity, pathogenesis, signs and symptoms, diagnostic testing and treatment algorithm
  • An overview of therapeutic pipeline activity for COVID-19 across the complete product development cycle including all clinical and non-clinical stages
  • Analyse the detailed profiles of COVID-19 therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, technologies and chemical information
  • Therapeutic assessment of the clinical pipeline products by stage, product type, molecule type, and route of administration
  • Detailed profiles of the clinical vaccines and listing of the non-clinical vaccines under development by companies
  • Listing of the vaccines under development by universities

 

 

 

Research Methodology for COVID-19 - Pipeline Analysis 2020

Overview of pipeline development activities for COVID-19 is not limited to drug description and development activities but also focuses on clinical and pre-clinical results. It also includes company collaboration, licensing deals, funds, and technology and patent details. Therapeutic segmentation of products for COVID-19 is done based on different stage of development. The report comprises of comparative pipeline therapeutics assessment along with detailed drug and vaccine profile of pipeline products by development stage, therapy type, molecule type, and administration route across this indication. Additionally, Executive summary have also been focused upon to give a summary regarding the current market scenario. The detailed profiles of the clinical vaccines products have been elucidated in the complete report and the non-clinical vaccines under development by companies and universities have also been listed.

Secondary Research

Detail secondary study was conducted to obtain the COVID-19 Pipeline Analysis through company internal sources such as quarterly reports, performance presentations, press releases, etc., and external sources including trade journals, news & articles, government publications, competitor publications, sector reports, regulatory body’s publications, safety standard organizations, third-party database and other creditable publications.

The secondary research on internal and external sources is being carried out to source qualitative and quantitative information relating to each market.

  • Company websites, quarterly reports, financial reports, broker reports, investor presentations and SEC filings
  • Industry trade journals and other literature
  • National government documents, statistical databases and market reports
  • News articles, press releases and web-casts specific to the companies operating in the market
  • Several databases for patents and clinical trials

Main objective of the COVID-19 - Pipeline Analysis 2020

The current pipeline trends of the COVID-19 are pinpointed in the study. Investors can gain strategic insights to base their discretion for investments from the qualitative and quantitative analysis performed in the study. Current and future pipeline trends would determine the overall attractiveness of the market, providing a platform for the industrial participant to exploit the untapped market to benefit as first mover advantage. The quantitative objectives for the report include:

  • Detailed overview of the indication including etiology, virology, diversity, pathogenesis, signs and symptoms, diagnostic testing and treatment algorithm
  • An overview of therapeutic pipeline activity for COVID-19 across the complete product development cycle including all clinical and non-clinical stages
  • Analyse the detailed profiles of COVID-19 therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, technologies and chemical information
  • Therapeutic assessment of the clinical pipeline products by stage, product type, molecule type, and route of administration
  • Detailed profiles of the clinical vaccines and listing of the non-clinical vaccines under development by companies
  • Listing of the vaccines under development by universities

 

 

 


COVID-19 – Pipeline Analysis 2020 for Global Market